<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301117</url>
  </required_header>
  <id_info>
    <org_study_id>TO-TAS-102-107</org_study_id>
    <nct_id>NCT02301117</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with
      advanced solid tumors and varying degrees of renal impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label study to evaluate the safety, tolerability, and
      pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of
      renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1) and
      the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment with
      TAS-102 during the study extension part only after completion of the Pharmacokinetic Part.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of FTD, FTY, and TPI in plasma after a single dose of TAS-102</measure>
    <time_frame>Blood samples will be collected in Cycle 1 Day 1 and Day 12 at pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours post AM dose of TAS-102</time_frame>
    <description>FTD, FTY and TPI: pharmacokinetic parameters Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2. FTD, FTY, and TPI: Ae% and CLr. FTD and TPI: CL/F, Vd/F of TAS-102</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety monitoring including adverse events, vital signs, and laboratory assessments</measure>
    <time_frame>Through 30 days following last administration of study medication or until initiation of new anticancer treatment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-102</intervention_name>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_label>Normal Renal Function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          1. Has provided written informed consent

          2. Has advanced solid tumors (excluding breast cancer)

          3. Has normal renal function, mild, moderate, or severe renal impairment and is not on
             dialysis

          4. ECOG performance status of â‰¤2

          5. Is able to take medications orally

          6. Has adequate organ function

          7. Women of childbearing potential must have a negative pregnancy test and must agree to
             adequate birth control if conception is possible. Males must agree to adequate birth
             control.

        Exclusion

          1. Certain serious illnesses or medical condition(s)

          2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,
             extended field radiation, received investigational agent, within the specified time
             frames prior to study drug administration

          3. Has received TAS-102

          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
             prior therapies

          5. Is a pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Winkler, MD</last_name>
    <phone>609-750-5300</phone>
    <email>rwinkler@taihooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Taiho Oncology, Inc</last_name>
    <phone>855-598-8259</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duarte Clinical Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Monica Clinical Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gainesville Clinical Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baltimore Clinical Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinical Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinical Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pittsburgh Clinical Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dallas Clinical Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brno Clinical Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praha Clinical Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belgrade Clinical Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sremska Kamenica Clinical Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winkler, MD</last_name>
      <phone>855-598-8259</phone>
      <email>rwinkler@taihooncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Renal Impairment</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Advance Solid Tumor</keyword>
  <keyword>Creatinine Clearance</keyword>
  <keyword>Kidney Neoplasms</keyword>
  <keyword>Renal Tumor</keyword>
  <keyword>Kidney</keyword>
  <keyword>Urology</keyword>
  <keyword>Pharmacologic Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

